New Center for Experimental Therapeutics in Cancer Advances Promising Treatments
Center will serve as a hub for commercialization of promising cancer therapies.
Cancer center scientists
“We see the Center for Experimental Therapeutics in Cancer as an incubator for bringing multidisciplinary teams from throughout UC Davis together with biotech and pharmaceutical companies working hard to move anti-cancer agents through the drug development pipeline, from start to finish,” Lam said.
The idea is to advance more effective, less toxic cancer therapies to meet the demand for precision medicine. These treatments target individual patients with care customized to specific cancer biomarkers, using the latest biological therapies and drug agents.
“The next frontier has arrived and we are poised to accelerate the discovery of novel cancer treatments based on a genetic understanding of a patient’s cancer,” said UC Davis Comprehensive Cancer Center Director Primo “Lucky” Lara Jr.
“Rather than a one-drug-fits-all approach, precision medicine is leveraging novel pathways, biomarkers and other discoveries, which we want to coordinate through this new center, designed to translate research quickly into clinical settings.”
The center will facilitate close collaboration with basic researchers, clinicians and translational scientists, including launching clinical trials to evaluate these newly identified anti-cancer agents. Researchers will work with pharma and biotech companies, venture capitalists, nonprofit foundations and academia, as well as the National Institutes of Health and National Cancer Institute.
In addition to rendering scientific and technical assistance, the Center for Experimental Therapeutics in Cancer will offer support for drug development by means of the Food and Drug Administration’s Investigational New Drug application process. The new center additionally will facilitate communication with UC Davis experts in intellectual property, licensing and patents.
“We also want to ensure ongoing educational opportunities such as workshops and symposiums in addition to helping advance the careers of researchers who come from underserved communities,” Gandara said. “We are committed to working with our
SOURCE: UC Davis Comprehensive Cancer Center
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- NCPA Announces Keynote Speaker for Annual Convention
September 18th 2025
- Upcoming NCPA Items for Pharmacy Teams: September and October 2025
September 11th 2025
- NCPA Applauds FTC Pick for Associate Director of Health Care
September 10th 2025
- NCPA Leads Huge Coalition in Letter Asking Congress to Pass PBM Reform Act
September 8th 2025